Si Eun Kim1,2, Byungju Lee3, Hyemin Jang1,4,5, Juhee Chin1,4,5, Ching Soong Khoo6, Yeong Sim Choe1,4,5,7, Ji Sun Kim1,4,5, Sung Hoon Kang1,4,5,8, Hang-Rai Kim1,4,5, Song Hwangbo1,4,5, Jee Hyang Jeong9, Soo Jin Yoon10, Kyung Won Park11, Eun-Joo Kim12, Bora Yoon13, Jae-Won Jang14, Jin Yong Hong15, Duk L Na1,4,5,7, Sang Won Seo1,4,5,16,17, Seong Hye Choi18, Hee Jin Kim19,20,21,22,23. 1. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Department of Neurology, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Korea. 3. Department of Neurology, Yuseong Geriatric Rehabilitation Hospital, Pohang, Korea. 4. Samsung Alzheimer Research Center, Samsung Medical Center, Seoul, Korea. 5. Neuroscience Center, Samsung Medical Center, Seoul, Korea. 6. Neurology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia. 7. Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea. 8. Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea. 9. Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University School of Medicine, Seoul, Korea. 10. Department of Neurology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea. 11. Department of Neurology, Dong-A Medical Center, Dong-A University College of Medicine, Busan, Korea. 12. Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Busan, Korea. 13. Department of Neurology, Konyang University College of Medicine, Daejeon, Korea. 14. Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Korea. 15. Department of Neurology, Yonsei University Wonju College of Medicine, Wonju, Korea. 16. Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea. 17. Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, Korea. 18. Department of Neurology, Inha University School of Medicine, Incheon, Korea. 19. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. evekhj@gmail.com. 20. Samsung Alzheimer Research Center, Samsung Medical Center, Seoul, Korea. evekhj@gmail.com. 21. Neuroscience Center, Samsung Medical Center, Seoul, Korea. evekhj@gmail.com. 22. Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea. evekhj@gmail.com. 23. Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, Korea. evekhj@gmail.com.
Abstract
BACKGROUND: The presence of ß-amyloid (Aß) in the brain can be identified using amyloid PET. In clinical practice, the amyloid PET is interpreted based on dichotomous visual rating, which renders focal Aß accumulation be read as positive for Aß. However, the prognosis of patients with focal Aß deposition is not well established. Thus, we investigated cognitive trajectories of patients with focal Aß deposition. METHODS: We followed up 240 participants (112 cognitively unimpaired [CU], 78 amnestic mild cognitive impairment [aMCI], and 50 Alzheimer's disease (AD) dementia [ADD]) for 2 years from 9 referral centers in South Korea. Participants were assessed with neuropsychological tests and 18F-flutemetamol (FMM) positron emission tomography (PET). Ten regions (frontal, precuneus/posterior cingulate (PPC), lateral temporal, parietal, and striatum of each hemisphere) were visually examined in the FMM scan, and participants were divided into three groups: No-FMM, Focal-FMM (FMM uptake in 1-9 regions), and Diffuse-FMM. We used mixed-effects model to investigate the speed of cognitive decline in the Focal-FMM group according to the cognitive level, extent, and location of Aß involvement, in comparison with the No- or Diffuse-FMM group. RESULTS: Forty-five of 240 (18.8%) individuals were categorized as Focal-FMM. The rate of cognitive decline in the Focal-FMM group was faster than the No-FMM group (especially in the CU and aMCI stage) and slower than the Diffuse-FMM group (in particular in the CU stage). Within the Focal-FMM group, participants with FMM uptake to a larger extent (7-9 regions) showed faster cognitive decline compared to those with uptake to a smaller extent (1-3 or 4-6 regions). The Focal-FMM group was found to have faster cognitive decline in comparison with the No-FMM when there was uptake in the PPC, striatum, and frontal cortex. CONCLUSIONS: When predicting cognitive decline of patients with focal Aß deposition, the patients' cognitive level, extent, and location of the focal involvement are important.
BACKGROUND: The presence of ß-amyloid (Aß) in the brain can be identified using amyloid PET. In clinical practice, the amyloid PET is interpreted based on dichotomous visual rating, which renders focal Aß accumulation be read as positive for Aß. However, the prognosis of patients with focal Aß deposition is not well established. Thus, we investigated cognitive trajectories of patients with focal Aß deposition. METHODS: We followed up 240 participants (112 cognitively unimpaired [CU], 78 amnestic mild cognitive impairment [aMCI], and 50 Alzheimer's disease (AD) dementia [ADD]) for 2 years from 9 referral centers in South Korea. Participants were assessed with neuropsychological tests and 18F-flutemetamol (FMM) positron emission tomography (PET). Ten regions (frontal, precuneus/posterior cingulate (PPC), lateral temporal, parietal, and striatum of each hemisphere) were visually examined in the FMM scan, and participants were divided into three groups: No-FMM, Focal-FMM (FMM uptake in 1-9 regions), and Diffuse-FMM. We used mixed-effects model to investigate the speed of cognitive decline in the Focal-FMM group according to the cognitive level, extent, and location of Aß involvement, in comparison with the No- or Diffuse-FMM group. RESULTS: Forty-five of 240 (18.8%) individuals were categorized as Focal-FMM. The rate of cognitive decline in the Focal-FMM group was faster than the No-FMM group (especially in the CU and aMCI stage) and slower than the Diffuse-FMM group (in particular in the CU stage). Within the Focal-FMM group, participants with FMM uptake to a larger extent (7-9 regions) showed faster cognitive decline compared to those with uptake to a smaller extent (1-3 or 4-6 regions). The Focal-FMM group was found to have faster cognitive decline in comparison with the No-FMM when there was uptake in the PPC, striatum, and frontal cortex. CONCLUSIONS: When predicting cognitive decline of patients with focal Aß deposition, the patients' cognitive level, extent, and location of the focal involvement are important.
Authors: Thomas G Beach; Lucia I Sue; Douglas G Walker; Marwan N Sabbagh; Geidy Serrano; Brittany N Dugger; Monica Mariner; Kim Yantos; Jonette Henry-Watson; Glenn Chiarolanza; Jose A Hidalgo; Leslie Souders Journal: J Alzheimers Dis Date: 2012 Impact factor: 4.472
Authors: Sid E O'Bryant; Laura H Lacritz; James Hall; Stephen C Waring; Wenyaw Chan; Zeina G Khodr; Paul J Massman; Valerie Hobson; C Munro Cullum Journal: Arch Neurol Date: 2010-06
Authors: Jung H Lee; Kang U Lee; Dong Y Lee; Ki W Kim; Jin H Jhoo; Ju H Kim; Kun H Lee; Sung Y Kim; Sul H Han; Jong I Woo Journal: J Gerontol B Psychol Sci Soc Sci Date: 2002-01 Impact factor: 4.077
Authors: Paul B Rosenberg; D F Wong; S L Edell; J S Ross; A D Joshi; J R Brašić; Y Zhou; V Raymont; A Kumar; H T Ravert; R F Dannals; M J Pontecorvo; D M Skovronsky; C G Lyketsos Journal: Am J Geriatr Psychiatry Date: 2013-03 Impact factor: 4.105
Authors: Christopher J Buckley; Paul F Sherwin; Adrian P L Smith; Jan Wolber; Sharon M Weick; David J Brooks Journal: Nucl Med Commun Date: 2017-03 Impact factor: 1.690
Authors: Michelle E Farrell; Kristen M Kennedy; Karen M Rodrigue; Gagan Wig; Gérard N Bischof; Jennifer R Rieck; Xi Chen; Sara B Festini; Michael D Devous; Denise C Park Journal: JAMA Neurol Date: 2017-07-01 Impact factor: 18.302
Authors: Sung Hoon Kang; Yu Hyun Park; Daun Lee; Jun Pyo Kim; Juhee Chin; Yisuh Ahn; Seong Beom Park; Hee Jin Kim; Hyemin Jang; Young Hee Jung; Jaeho Kim; Jongmin Lee; Ji-Sun Kim; Bo Kyoung Cheon; Alice Hahn; Hyejoo Lee; Duk L Na; Young Ju Kim; Sang Won Seo Journal: Dement Neurocogn Disord Date: 2019-10-02
Authors: Byoung Seok Ye; Hee Jin Kim; Yeo Jin Kim; Na-Yeon Jung; Jin San Lee; Juyoun Lee; Young Kyoung Jang; Jin-Ju Yang; Jong-Min Lee; Jacob W Vogel; Duk L Na; Sang Won Seo Journal: Sci Rep Date: 2018-04-03 Impact factor: 4.379
Authors: Charles F Murchison; Byron C Jaeger; Jeff M Szychowski; Gary R Cutter; Erik D Roberson; Richard E Kennedy Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160